Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

In 2023, opioid settlement funds flowed to states. Here's how it's going

Some $1.5 billion flowed to local government coffers this year, sparking debates about transparency and how to spend the money. Here are 5 takeaways from a year's worth of reporting on the issue.

WEKU

3 Pharma Powerhouses to Watch Closely

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Therefore, it could be wise to keep an eye on top pharma stocks, Roche Holding (RHHBY), Novartis (NVS) and AbbVie (ABBV). Continue reading.

StockNews.com

Bold Brews Beat Weight-Loss Drugs: Nestle CEO's Confident Declaration

Weight-loss drugs no match for Nestle's coffee empire, claims CEO. Discover how Nestle plans to keep their caffeine-filled kingdom thriving!

Top News

From analysis to the latest developments in health,
read the most diverse news in one place.

Analyzing 3 Pharma Stocks for Year-End Gains?

The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read…

StockNews.com

Analyzing Buy or Hold Options for 3 Medical Stocks

The medical industry is thriving due to rising demand for healthcare products and services, fueling significant returns. Given the solid long-term prospects of the industry, let’s analyze fundamentally sound medical stocks McKesson (MCK), Zimmer Biomet (ZBH) and Fresenius SE (FSNUY).

StockNews.com

Pfizer Sues Poland And Hungary Over Covid Debts

Pharmaceutical firms Pfizer and BioNTech are suing the governments of Poland and Hungary alleging they failed to pay for vaccines ordered during the Covid pandemic, lawyers said Tuesday.

International Business Times

The good news for women: a drug to limit hot flushes. The bad: it could cost you £430 a month

Veoza reduces the severity of this common menopausal symptom. But at £430 a month, only the wealthy will gain just now, says Guardian columnist Devi Sridhar

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

How the Michelle Mone scandal unfolded: £200m of PPE contracts, denials and a government lawsuit

Conservative peer made multiple denials of any association between her and PPE Medpro

The Guardian - UK

Supreme Court to Review Nationwide Restrictions on Abortion Pill

US Supreme Court to decide on restricting abortion drug Mifepristone. Attorney General Bob Ferguson discusses potential ramifications and possible tactics.

Top News

Stakeholders express dismay as Centre readies to regulate medical devices alongside drugs

Concerned groups express dismay over proposed New Drugs, Cosmetics and Medical Device Bill, 2023, citing inadequate addressing of key issues and lack of external input.

The Hindu

FDA Spots Control Irregularities in Moderna's US Plant

Dive into the intriguing saga of unanticipated control failures at Moderna's magnate production plant, a juicy scoop exclusively unraveled by the meticulou...

Top News

Older Americans to pay less for some drug treatments as drugmakers penalized for big price jumps

Hundreds of thousands of older Americans could pay less for outpatient drug treatments beginning early next year

The Independent UK

Vivek Ramaswamy spins conspiracy theories at bad-tempered CNN town hall

Republican presidential candidate sparred with host Abby Phillip at Iowa event

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

Pfizer Shares Tumble On Disappointing 2024 Profit Outlook

Pfizer issued a disappointing 2024 forecast Wednesday, denting shares as the company navigates a profound plunge in sales tied to the Covid-19 pandemic.

Top News

Supreme Court to Consider Restrictions on Abortion Drug Mifepristone

The Supreme Court is reconsidering the accessibility of popular abortion drug, Mifepristone, a high-stakes case with potential electoral repercussions.

The Hindu

Committee recommends curbs on freebies doled out by pharma companies

Committee recommends revising UCPMP to prohibit CMEs in foreign locations, disclose price of gifts to doctors, and make money received by doctors from pharma cos for research taxable.

Top News

FDA Seeks Power for Eyedrops Recalls Amid Foreign Inspections Woes

U.S. health officials grapple with inadequate inspection of overseas eyedrop factories, leading to recalls of potentially dangerous products.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Safer eyedrops will require new FDA powers and resources, experts say

Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas

The Guardian - UK

AstraZeneca buys US vaccine company in $1.1bn deal

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

StockNews.com

Citius Pharmaceuticals (CTXR) Earnings Watch: Pharma Stock Signals for Investors

Citius Pharmaceuticals (CTXR) has been making significant progress in its pipeline, garnering investors' attention. However, considering that CTXR is an unprofitable and pre-revenue business, is it worth investing now as the company prepares to report quarterly results? Keep reading.

StockNews.com

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

StockNews.com

3 Pharma Stocks Flashing 'Buy' Signals in December

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

The Independent UK

DeSantis raises eyebrows by telling GOP debate his favourite president is Calvin Coolidge

‘He’s one of the few presidents that got almost everything right. He understood the proper role of the federal government under the Constitution,’ DeSantis says

The Hindu

DCA busts spurious anti-cancer drug racket, ₹4.35 crore stock seized

1 … 37 38 39 40

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

National Crime Agency

304 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.